Sign in
Explore the registryTrack Oral repotrectinib's trials

TRIDENT-1

A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements

Oral repotrectinib (TPX-0005)OngoingRecruitingPhase 1Open NCT03093116 on ClinicalTrials.gov ↗

Population

Loading…

Intervention

Loading…

Comparator

Loading…

Loading…